Osteopontin is a prognostic biomarker in non-small cell lung cancer-Reference-Cited by-同舟云学术

Osteopontin is a prognostic biomarker in non-small cell lung cancer

Published:2013-11-11 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Rud Ane Kongsgaard,Boye Kjetil,Øijordsbakken Miriam,Lund-Iversen Marius,Halvorsen Ann Rita,Solberg Steinar K,Berge Gisle,Helland Åslaug,Brustugun Odd Terje,Mælandsmo Gunhild M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-540.pdf

Reference32 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.

2. Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, et al: Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer. 2012, 76: 431-438. 10.1016/j.lungcan.2011.12.004.

3. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA: Non-small-cell lung cancer. Lancet. 2011, 378: 1727-1740. 10.1016/S0140-6736(10)62101-0.

4. Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Maelandsmo GM, Boye K: Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer. 2012, Aug 1, 12: 333-10.1186/1471-2407-12-333.

5. Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010, 176: 528-535. 10.2353/ajpath.2010.090526.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review;Biomarkers;2024-02-17

2. Common Variants in Osteopontin and CD44 Genes as Predictors of Treatment Outcome in Radiotherapy and Chemoradiotherapy for Non-Small Cell Lung Cancer;Cells;2023-11-28

3. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer;Cancers;2023-09-14

4. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures;Journal for ImmunoTherapy of Cancer;2023-07

5. “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”;Diagnostic Pathology;2023-05-27